Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — Juni 2020

Biotek-snakken — Juni 2020

Planlagt Fastgjort Låst Flyttet Biotek-snakken
265 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • B Offline
    B Offline
    bb
    wrote on sidst redigeret af
    #250

    Cantor Fitzgerald analyst Brandon Folkes maintained an Overweight rating and $18 price target on Chiasma. The analyst said that the FDA approval for Mycapssa for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide is a "giant leap" for Chiasma. He sees Mycapssa, as the only approved oral octreotide, gaining meaningful share in the market once launch in Q4.

    1 Reply Last reply
    0
    • B Offline
      B Offline
      bb
      wrote on sidst redigeret af
      #251

      Folkes added that the negative reaction to the approval is "unwarranted," as "the label, pricing and launch timing were all in line" with his expectations.

      1 Reply Last reply
      0
      • B Offline
        B Offline
        BioShare
        wrote on sidst redigeret af
        #252

        Tak for info bb+ - det var noget af en upside risiko 🙂 Men noget besynderlig udvikling...må være en stor aktionær som bare ville ud (ret stor volumen). Men fine kurstargets...

        1 Reply Last reply
        0
        • M Offline
          M Offline
          Mcjean
          wrote on sidst redigeret af
          #253

          https://www.smarteranalyst.com/new-blurbs/analysts-offer-insights-on-healthcare-companies-chimerix-cmrx-and-bergenbio-as-otherbrrgf/ BGBIO 66 kr.

          1 Reply Last reply
          0
          • Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktør
            wrote on sidst redigeret af
            #254

            Test

            1 Reply Last reply
            0
            • F Offline
              F Offline
              Fandel
              wrote on sidst redigeret af
              #255

              God morgen til alle...

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #256

                https://www.trinitydelta.org/wp-content/uploads/2020/06/BerGenBio-Outlook-200629.pdf

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #257

                  Slide 23 Rigel andel i bemcentinib (BergenBio)

                  1 Reply Last reply
                  0
                  • B Offline
                    B Offline
                    BioShare
                    wrote on sidst redigeret af
                    #258

                    Tak for link sukkeralf 🙂

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bb
                      wrote on sidst redigeret af
                      #259

                      HRTX fik et CRL fra FDA - aktien falder 28% øv. https://finance.yahoo.com/news/heron-therapeutics-receives-complete-response-124500540.html

                      1 Reply Last reply
                      0
                      • B Offline
                        B Offline
                        bb
                        wrote on sidst redigeret af
                        #260

                        The CRL stated that the FDA is unable to approve the NDA in its present form based on the need for additional non-clinical information. Based on the complete review of the NDA, the FDA did not identify any clinical safety or efficacy issues or CMC issues. There are four non-clinical issues in the CRL, none of which relate to any observed toxicity. Three relate to confirming exposure of excipients in preclinical reproductive toxicology studies, and the fourth relates to changing the manufacturing

                        1 Reply Last reply
                        0
                        • B Offline
                          B Offline
                          bb
                          wrote on sidst redigeret af
                          #261

                          release specification of the allowable level of an impurity based on animal toxicology coverage. We do not believe that any of the issues are significant barriers to ultimate approval, as all of the excipients have extensive histories of use in pharmaceuticals and the specification can be revised. The Company will request a Type A meeting to obtain agreement with the Agency on our responses and resubmit the application as quickly as possible.

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #262

                            Phesgo godkendt

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #263

                              Just a moment...

                              favicon

                              (www.firstwordpharma.com)

                              1 Reply Last reply
                              0
                              • B Offline
                                B Offline
                                bikube
                                wrote on sidst redigeret af
                                #264

                                Det trækk
                                er lige Halo op med 4.2%

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #265

                                  Zymes opdatering

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #266

                                    favicon

                                    (finance.yahoo.com)

                                    1 Reply Last reply
                                    0

                                    Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                    Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                    With your input, this post could be even better 💗

                                    Tilmeld Log ind
                                    Svar
                                    • Svar som emne
                                    Login for at svare
                                    • Ældste til nyeste
                                    • Nyeste til ældste
                                    • Most Votes


                                    • Log ind

                                    • Har du ikke en konto? Tilmeld

                                    • Login or register to search.
                                    Powered by NodeBB Contributors
                                    • First post
                                      Last post
                                    0
                                    • Kategorier
                                    • Seneste
                                    • Etiketter
                                    • Populære
                                    • Verden
                                    • Bruger
                                    • Grupper